文献速递糖尿病肥胖与代谢综合征

PCSK9基因变异与2型糖尿病风险:一项孟德尔随机化研究

PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.
PubMed 文献 · Lancet Diabetes Endocrinol · 2016-11-29

该孟德尔随机化研究利用超过55万人的数据,分析四种PCSK9基因变异与2型糖尿病及相关生物标志物的关联。结果显示,PCSK9变异所致LDL胆固醇降低与空腹血糖、体重、腰臀比升高及2型糖尿病风险增加相关,但与HbA1c、空腹胰岛素和BMI无显著关联。作者建议在PCSK9抑制剂试验中仔细评估这些安全性结局。

要点

  • 四种PCSK9变异联合分析,LDL胆固醇每降低1 mmol/L,2型糖尿病OR为1.29(95%CI 1.11-1.50)。
  • LDL胆固醇每降低1 mmol/L与空腹血糖升高0.09 mmol/L(95%CI 0.02-0.15)相关。
  • LDL胆固醇每降低1 mmol/L与体重增加1.03 kg(95%CI 0.24-1.82)及腰臀比增加0.006(95%CI 0.003-0.010)相关。

核心结论

  • 与较低LDL胆固醇相关的PCSK9变异也与较高的空腹血糖、体重、腰臀比及2型糖尿病风险增加相关。
  • 作者建议在PCSK9抑制剂试验中仔细评估这些安全性结局,并量化PCSK9抑制剂治疗的风险与获益,如同既往对他汀类药物所做的那样。

研究设计与样本

  • 孟德尔随机化研究,使用队列研究、随机对照试验、病例对照研究和遗传联盟的数据。
  • 数据覆盖超过550 000名个体和51 623例2型糖尿病病例。
  • 采用标准化分析计划、荟萃分析和加权基因中心评分,分析四种独立PCSK9变异(rs11583680、rs11591147、rs2479409和rs11206510)与LDL胆固醇、空腹血糖、HbA1c、空腹胰岛素、体重、腰臀比、BMI及2型糖尿病风险的关联。

主要发现

  • 四种PCSK9变异联合分析按LDL胆固醇降低1 mmol/L缩放后,与空腹血糖升高0.09 mmol/L(95%CI 0.02-0.15)相关。
  • 与体重增加1.03 kg(95%CI 0.24-1.82)、腰臀比增加0.006(95%CI 0.003-0.010)及2型糖尿病OR 1.29(95%CI 1.11-1.50)相关。
  • 未发现与HbA1c(0.03%,95%CI -0.01-0.08)、空腹胰岛素(0.00%,95%CI -0.06-0.07)和BMI(0.11 kg/m2,95%CI -0.09-0.30)的关联。

临床怎么用

  • 作者建议在PCSK9抑制剂试验中仔细评估这些安全性结局并量化PCSK9抑制剂治疗的风险与获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Statin treatment and variants in the gene encoding HMG-CoA reductase are associated with reductions in both the concentration of LDL cholesterol and the risk of coronary heart disease, but also with modest hyperglycaemia, increased bodyweight, and modestly increased risk of type 2 diabetes, which in no way offsets their substantial benefits. We sought to investigate the associations of LDL cholesterol-lowering PCSK9 variants with type 2 diabetes and related biomarkers to gauge the likely effects of PCSK9 inhibitors on diabetes risk. METHODS: In this mendelian randomisation study, we used data from cohort studies, randomised controlled trials, case control studies, and genetic consortia to estimate associations of PCSK9 genetic variants with LDL cholesterol, fasting blood glucose, HbA1c, fasting insulin, bodyweight, waist-to-hip ratio, BMI, and risk of type 2 diabetes, using a standardised analysis plan, meta-analyses, and weighted gene-centric scores. FINDINGS: Data were available for more than 550 000 individuals and 51 623 cases of type 2 diabetes. Combined analyses of four independent PCSK9 variants (rs11583680, rs11591147, rs2479409, and rs11206510) scaled to 1 mmol/L lower LDL cholesterol showed associations with increased fasting glucose (0·09 mmol/L, 95% CI 0·02 to 0·15), bodyweight (1·03 kg, 0·24 to 1·82), waist-to-hip ratio (0·006, 0·003 to 0·010), and an odds ratio for type diabetes of 1·29 (1·11 to 1·50). Based on the collected data, we did not identify associations with HbA1c (0·03%, -0·01 to 0·08), fasting insulin (0·00%, -0·06 to 0·07), and BMI (0·11 kg/m2, -0·09 to 0·30). INTERPRETATION: PCSK9 variants associated with lower LDL cholesterol were also associated with circulating higher fasting glucose concentration, bodyweight, and waist-to-hip ratio, and an increased risk of type 2 diabetes. In trials of PCSK9 inhibitor drugs, investigators should carefully assess these safety outcomes and quantify the risks and benefits of PCSK9 inhibitor treatment, as was previously done for statins. FUNDING: British Heart Foundation, and University College London Hospitals NHS Foundation Trust (UCLH) National Institute for Health Research (NIHR) Biomedical Research Centre.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Schmidt AF, Swerdlow DI, Holmes MV, et al. PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. Lancet Diabetes Endocrinol. 2016. PMID: 27908689. doi:10.1016/S2213-8587(16)30396-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。